Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KJ-C2635
- Development stage
- Preclinical
- Lead developer
- CARsgen Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
KJ-C2635 is an experimental in vivo chimeric antigen receptor (CAR) T-cell therapy being developed by CARsgen Therapeutics for the treatment of hepatocellular carcinoma (HCC) and other GPC3-positive solid tumors. Unlike traditional ex vivo CAR-T therapies that require leukapheresis and external cell engineering, KJ-C2635 is designed to generate CAR-T cells directly within the patient's body using a viral or non-viral delivery vector. The therapy targets Glypican-3 (GPC3), a cell-surface oncofetal proteoglycan that is highly overexpressed in liver cancer but has limited expression in normal adult tissues. By engineering T cells in situ to express a GPC3-specific CAR, the therapy aims to provide a more accessible and scalable treatment option for liver cancer patients. As of 2026, the program is in the pre-clinical stage of development.
- Other names
- KJ-C2635KJ-C-2635KJ-C 2635
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on KJ-C2635.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KJ-C2635.